No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P-glycoprotein.


Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
08 2019
Historique:
received: 20 12 2018
accepted: 23 01 2019
pubmed: 11 2 2019
medline: 16 4 2020
entrez: 11 2 2019
Statut: ppublish

Résumé

Hypericum perforatum L. (St. John's wort) is used to treat mild-to-moderate depression. Its potential safety risks are pharmacokinetic drug interactions via cytochrome P450 (CYP) enzymes and P-glycoprotein, presumably caused by hyperforin. In a phase I, open-label, nonrandomized, single-sequence study, the low-hyperforin Hypericum extract Ze 117 was investigated using a drug cocktail in 20 healthy volunteers. No pharmacokinetic interactions of Ze 117 were observed for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4, and P-glycoprotein. Area under the curve (AUC) and peak plasma concentration (C

Identifiants

pubmed: 30739325
doi: 10.1002/cpt.1392
pmc: PMC6766782
doi:

Substances chimiques

ATP Binding Cassette Transporter, Subfamily B, Member 1 0
Plant Extracts 0
Psychotropic Drugs 0
Terpenes 0
ZE 117 0
Dextromethorphan 7355X3ROTS
Cytochrome P-450 Enzyme System 9035-51-2
Phloroglucinol DHD7FFG6YS
hyperforin RM741E34FP

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

432-440

Informations de copyright

© 2019 Max Zeller & Söhne AG. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Références

Clin Pharmacol Ther. 1999 Oct;66(4):338-45
pubmed: 10546917
Lancet. 2000 Feb 12;355(9203):548-9
pubmed: 10683008
Int Clin Psychopharmacol. 2000 Mar;15(2):61-8
pubmed: 10759336
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7500-2
pubmed: 10852961
J Pharmacol Exp Ther. 2000 Jul;294(1):88-95
pubmed: 10871299
BMJ. 2000 Sep 2;321(7260):536-9
pubmed: 10968813
Clin Pharmacol Ther. 2001 Oct;70(4):317-26
pubmed: 11673747
JAMA. 2003 Sep 17;290(11):1500-4
pubmed: 13129991
Clin Pharmacol Ther. 2004 Mar;75(3):191-7
pubmed: 15001970
Br J Clin Pharmacol. 2004 Apr;57(4):495-9
pubmed: 15025748
Drug Metab Dispos. 2004 May;32(5):512-8
pubmed: 15100173
J Clin Pharmacol. 2004 Jun;44(6):577-81
pubmed: 15145964
Clin Pharmacol Ther. 2004 Jun;75(6):546-57
pubmed: 15179409
Drug Saf. 2004;27(11):773-97
pubmed: 15350151
Clin Pharmacol Ther. 2004 Oct;76(4):330-40
pubmed: 15470332
Planta Med. 2005 Apr;71(4):331-7
pubmed: 15856409
Drugs Aging. 2005;22(6):525-39
pubmed: 15974642
Eur J Clin Pharmacol. 2006 Mar;62(3):225-33
pubmed: 16477470
Planta Med. 2006 Jun;72(8):685-90
pubmed: 16755466
Br J Clin Pharmacol. 2006 Nov;62(5):512-26
pubmed: 17010103
Br J Pharmacol. 2008 Apr;153(7):1579-86
pubmed: 18204476
Mol Nutr Food Res. 2008 Jul;52(7):755-63
pubmed: 18214849
Eur J Clin Pharmacol. 2009 Jan;65(1):81-7
pubmed: 18762932
Cochrane Database Syst Rev. 2008 Oct 08;(4):CD000448
pubmed: 18843608
Eur J Clin Pharmacol. 2009 Mar;65(3):287-94
pubmed: 19015839
Eur J Pharm Sci. 2009 Mar 2;36(4-5):433-43
pubmed: 19073252
Clin Pharmacol Ther. 2010 Nov;88(5):652-9
pubmed: 20881954
Oncologist. 2011;16(6):820-34
pubmed: 21632461
Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):691-708
pubmed: 22606944
Drug Metabol Drug Interact. 2012;27(4):185-97
pubmed: 23152403
Drug Metab Dispos. 2013 May;41(5):987-93
pubmed: 23401474
Phytother Res. 2014 May;28(5):643-55
pubmed: 23897801
Clin Pharmacol Ther. 2014 Sep;96(3):349-59
pubmed: 24722393
Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):125-38
pubmed: 25465228
Wien Med Wochenschr. 2015 Jun;165(11-12):229-35
pubmed: 26183728
Basic Clin Pharmacol Toxicol. 2016 Sep;119(3):284-90
pubmed: 27009433
Front Pharmacol. 2016 Nov 21;7:443
pubmed: 27917125
Clin Pharmacol Ther. 2017 Jul;102(1):37-44
pubmed: 27997040
J Pharm Pharm Sci. 2016 Oct - Dec;19(4):520-529
pubmed: 28057170
Br J Clin Pharmacol. 2018 Mar;84(3):501-509
pubmed: 29178272

Auteurs

Catherine Zahner (C)

Max Zeller Soehne AG, Romanshorn, Switzerland.

Esther Kruttschnitt (E)

Max Zeller Soehne AG, Romanshorn, Switzerland.

Julia Uricher (J)

Max Zeller Soehne AG, Romanshorn, Switzerland.

Michael Lissy (M)

Nuvisan GmbH, Neu-Ulm, Germany.

Martin Hirsch (M)

Nuvisan GmbH, Neu-Ulm, Germany.

Simon Nicolussi (S)

Max Zeller Soehne AG, Romanshorn, Switzerland.

Stephan Krähenbühl (S)

Division of Clinical Pharmacology & Toxicology, University Hospital, Basel, Switzerland.

Jürgen Drewe (J)

Max Zeller Soehne AG, Romanshorn, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH